5 hours Zacks Research Weighs in on Catalyst Pharmaceuticals, Inc.’s Q3 2025 Earnings (NASDAQ:CPRX) MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) – Stock analysts at Zacks Research raised their Q3 2025 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a research report issued to clients and investors on Thursday, Octo…
Earnings · Nasdaq 100 · Pharmaceuticals · Science